Acuta Capital Partners, LLC Eye Point Pharmaceuticals, Inc. Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.71 - $24.13 $713,750 - $3.02 Million	125,000 Added 41.65%	425,128 $9.82 Million
Q3 2023 Nov 14, 2023	SELL	$7.99 - $15.36 $654,157 - $1.26 Million	-81,872 Reduced 21.43%	300,128 $2.4 Million
Q2 2023 Aug 14, 2023	BUY	$3.03 - $9.0 $238,170 - $707,436	78,604 Added 25.91%	382,000 $3.32 Million
Q2 2022 Aug 15, 2022	SELL	$7.25 - $12.71 $32,973 - $57,805	-4,548 Reduced 1.48%	303,396 $2.39 Million
Q1 2022 May 16, 2022	BUY	$8.67 - $14.11 $562,440 - $915,343	64,872 Added 26.69%	307,944 $3.74 Million
Q4 2021 Feb 14, 2022	SELL	$10.18 - $18.4 $1.29 Million - $2.33 Million	-126,791 Reduced 34.28%	243,072 $2.98 Million
Q2 2021 Aug 16, 2021	SELL	$8.69 - $11.08 $98,040 - $125,004	-11,282 Reduced 2.96%	369,863 $3.33 Million
Q1 2021 May 17, 2021	BUY	$8.89 - $14.92 $3.39 Million - $5.69 Million	381,145 New	381,145 $3.87 Million

163

58.2M

224K

1.41M

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $272M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.